Kazia Therapeutics Public Offering Overview
Kazia Therapeutics Ltd ADR (NASDAQ:KZIA) saw its shares decline 6.2% in pre‑market trading on Friday after the company priced a registered public offering at $15.50 per American Depositary Share (ADS). The offering is expected to generate approximately $40 million in gross proceeds before fees.
The company will sell 2,580,000 ADS, each ADS representing 500 ordinary shares. In addition, the offering includes Series A warrants that allow the purchase of up to 2,243,478 ADS at $17.825 per ADS and Series B warrants that permit the purchase of up to 2,064,000 ADS at $19.375 per ADS.
Series A warrants are exercisable immediately and will expire on the earlier of (i) 30 days after the company’s Stage IV triple‑negative breast‑cancer data readout, expected in the second half of 2027, or (ii) the five‑year anniversary of issuance. Series B warrants will expire on the earlier of (i) 30 days after the HR+/HER2‑ breast‑cancer data readout, expected in the first half of 2028, or (ii) the five‑year anniversary of issuance. If all warrants are exercised in full, Kazia would receive an additional approximately $80 million in gross proceeds before expenses.
Leerink Partners and Guggenheim Securities are acting as joint book‑running managers, with BTIG and Needham & Company serving as lead managers. The offering is slated to close on or about August 31, 2026, subject to customary closing conditions.
Kazia stated that the net proceeds will be primarily used to fund the clinical development of paxalisib, its lead oncology asset, across multiple cancer indications, including ongoing and planned studies in triple‑negative breast cancer and HR+/HER2‑ breast cancer, as well as for working capital and general corporate purposes.